BC Innovations | Nov 18, 2019
Distillery Therapeutics

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BioCentury | Sep 17, 2019
Regulation

FDA’s international drug review pilot could simplify cancer trials, get drugs to patients faster

FDA believes its new framework for the submission and review of cancer drugs concurrently in multiple countries will speed up patient access to new therapies and streamline drug development. The agency unveiled the framework, dubbed...
BC Extra | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
BC Innovations | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Dec 7, 2018
Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners. Existing investors 5AM Ventures,...
BC Extra | Dec 6, 2018
Financial News

Impel raises $67.5M series D

Impel NeuroPharma Inc. (Seattle, Wash.) hopes to accelerate its clinical portfolio of intranasal CNS therapies with a $67.5 million series D round led by new investors KKR and Norwest Venture Partners. Existing investors 5AM Ventures,...
BC Extra | Aug 23, 2018
Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
BC Week In Review | Aug 17, 2018
Clinical News

FDA approves Eisai's Lenvima for first-line HCC

FDA approved Lenvima lenvatinib mesylate from Eisai Co. Ltd. (Tokyo:4523) as first-line treatment of unresectable hepatocellular carcinoma (HCC). The approval was based on data from the Phase III REFLECT trial in patients with previously untreated,...
Items per page:
1 - 10 of 470